You are here

  • Home
  • Archive
  • Volume 76, Issue 3
  • Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
Free

https://doi.org/10.1136/annrheumdis-2014-207178corr1

Statistics from Altmetric.com

    Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 2016;75:1293–1301. The second trial number has been corrected to NCT00550446

    Linked Articles